Impact of alcohol consumption on survival in patients with esophageal carcinoma: a large cohort with long-term follow-up.
Bottom Line: The median overall survival (OS; 42 months) and disease-free survival (DFS; 33 months) for never-drinkers were significantly higher than ever-drinkers (27 and 22 months, respectively).The hazardous effect on OS and DFS of drinking grew statistically significantly in a dose-dependent manner with increasing amount of alcohol consumption per day (both P-value for trend < 0.05).The predictive effect of drinking on OS (P = 0.596) or DFS (P = 0.207) was not significant in the subgroup with esophageal adenocarcinoma (n = 195).
Affiliation: Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China; Guangdong Esophageal Cancer Institute, Guangzhou, China.Show MeSH
Related in: MedlinePlus
Mentions: In patients with ESCC, ever-drinkers had significantly poorer OS (median, 49 months vs 28 months, P < 0.001) (Fig. 2a) and DFS (median, 36 months vs 22 months, P < 0.001) (Fig. 2b). Among patients with EAC, including adenocarcinoma of the esophagogastric junction, there was no significant difference between never- and ever-drinkers in OS (median, 31 months vs 25 months, P = 0.660) (Fig. 2c) or DFS (median, 23 months vs 17 months, P = 0.729) (Fig. 2d). In model C, adjusted for baseline covariates, smoking status, and gender, drinking status was found to be an independent prognostic factor for poorer OS (HR, 1.19; 95% CI, 1.03–1.38; P = 0.022) and DFS (HR, 1.18; 95% CI, 1.02–1.36; P = 0.023) in patients with ESCC. Among patients with EAC, drinking status was not a significant prognostic factor for OS (HR, 1.27; P = 0.596) or DFS (HR, 1.77; P = 0.207) (Table S2). In addition, the dose–response relationship also existed in the ESCC subgroup (Table S3).
Affiliation: Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China; Guangdong Esophageal Cancer Institute, Guangzhou, China.